Planned population
Adults with advanced extracranial solid tumors and safely accessible lesions. A multidisciplinary team would assess standard curative options, organ function and clinical status.
CDX-101
Study design, outcomes and participation information for the planned Phase 1 study.
View ClinicalTrials.gov record NCT07911293
Research interest registration is open The study team will publish site and screening details when enrollment opens.
U.S. patients can register their interest now. Once a U.S. study site opens enrollment, the site team will announce screening arrangements and assess eligibility under the applicable protocol.
U.S. study interest formSingle-patient expanded access is a U.S. pathway for potential investigational treatment outside a clinical trial. For a non-emergency request, the treating physician contacts the sponsor to discuss availability for the individual patient and the next steps.
The physician reviews trial access, available alternatives, and whether the potential benefit justifies the risk for a patient with a serious or immediately life-threatening condition.
Ask whether CDX-101 can be supplied for this patient. If the sponsor agrees, request a Letter of Authorization (LOA) allowing FDA to reference IND 184255. The IND number alone does not authorize treatment.
For a physician-sponsored non-emergency request, the physician files Form FDA 3926 and the LOA, if provided. The physician arranges Institutional Review Board review or eligible concurrence under the FDA procedure.
For a non-emergency individual-patient IND, the FDA waiting period is generally 30 days after receipt unless FDA allows an earlier start. Before proceeding, the physician confirms the request can go ahead, completes applicable IRB requirements and obtains informed consent. The physician then monitors the patient and makes required reports.
FDA physician submission guideOfficial Form FDA 3926 guidanceFDA information for patients
Local simulation. Use fictional information and dummy files only. Nothing is submitted, saved or reviewed by a study team.
Anyone can complete this inquiry. Add the physician and clinical information if available.
Patients outside China who are interested in traveling to China can submit a pre-registration here. Beijing Hospital is the proposed China study site. The research team will announce international screening, visits, language support and costs when that pathway opens.
The China draft describes 1–10 eligible target lesions, each no larger than 10 cm, and allows other non-target lesions to be recorded. Screening is based on the applicable approved protocol and investigator review.
The China clinical trial is free of charge to participants. This covers study treatment, protocol-required tests and follow-up.
International patient coordination fee · USD 6,000 International patients using this pathway pay a separate fee for coordination services. The team will provide the fee details in writing before payment.
Local simulation. Use fictional information and dummy files only. Nothing is submitted, saved or reviewed by a study team.
Pre-registration helps the study team contact you and conduct a preliminary review. Pre-registration does not guarantee enrollment or constitute a medical commitment.
The planned Phase 1 study is prospective, open-label and single-arm, in adults with advanced extracranial solid tumors. The v3.0 protocol under the U.S. IND describes a safety lead-in followed by review by an independent data safety monitoring board and expansion to approximately 50 participants. The China protocol is managed separately.
Adults with advanced extracranial solid tumors and safely accessible lesions. A multidisciplinary team would assess standard curative options, organ function and clinical status.
Dose-limiting toxicities, adverse events and serious adverse events. Containment measures include visible extra-lesional distribution, mandatory stops and non-target tissue injury.
Lesion- and patient-level complete non-viable response (CNVR), extent of necrosis, local control and durability, RECIST 1.1, patient-reported outcomes, reaction products and hematologic measures.
Beijing Hospital is named as the proposed initial site. The study team will announce the enrollment process when the site opens. Imaging or direct visualization is used to monitor distribution in the proposed research.
Protocol v3.0 §§3–5, 7–10 · 2026-11-19
The site accepts research interest registrations. The study team will announce the start date and screening process when enrollment opens.
When recruitment opens, investigators will assess suitability under the applicable ethics-approved protocol and formal consent process.
The research team can review your inquiry and follow up using the contact information you provide if you agree to be contacted. Formal screening and enrollment follow the study’s separate process.
We plan to continue expanding clinical development beyond Phase 1 and ultimately complete a confirmatory trial. We expect image-guided intratumoral injection to remain the core approach. Later study protocols will reflect the safety and response findings from earlier studies.
In a planned study population whose identified tumors can all be treated safely under the protocol, our development goal across phases is a 95% patient-level complete response rate. The proposed approach is to treat all such lesions, with up to four injection sessions per lesion, aiming for the lesions to become undetectable on follow-up imaging. Complete response will be assessed at the patient level using the study’s prespecified criteria.